Tumor Stroma Imaging Agent with FAP Targeting
Summary
USPTO granted patent US12599685B2 to Shanghai University of Medicine & Health Sciences for a tumor stroma imaging agent targeting fibroblast activation protein (FAP). The imaging agent exhibits high affinity for FAP, high uptake for malignant tumors with high FAP expression, and high sensitivity and specificity for tumor diagnosis. The patent covers the chemical structure where R is hydrogen or fluorine, and claims the agent's use for malignant tumor diagnosis and treatment with prolonged half-life.
What changed
USPTO issued patent US12599685B2 granting Shanghai University of Medicine & Health Sciences exclusive rights to a tumor stroma imaging agent targeting fibroblast activation protein (FAP). The patent covers the chemical compound where R is hydrogen or fluorine, classified under A61K 51/0497 and related pharmaceutical compositions.
For pharmaceutical manufacturers and medical device companies developing diagnostic agents for oncology, this patent establishes intellectual property protection for FAP-targeted tumor imaging. Entities developing similar imaging agents or diagnostics for malignant tumors should consider potential licensing needs or design-around strategies to avoid infringement on the 15 granted claims.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tumor stroma imaging agent and preparation method thereof
Grant US12599685B2 Kind: B2 Apr 14, 2026
Assignee
SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES
Inventors
Gang Huang, Bin Li
Abstract
A tumor stroma imaging agent with a chemical structural formula (I):
is provided, where R is hydrogen or fluorine. Compared with the prior art, the tumor stroma imaging agent exhibits significant affinity for fibroblast activation protein (FAP), high uptake for a malignant tumor with high FAP expression in a tumor stroma, and high sensitivity and specificity for the diagnosis of a malignant tumor, and is not prone to false positives. Therefore, the tumor stroma imaging agent can be effectively and safely used for the diagnosis and treatment of various malignant tumors with a prolonged half-life and an extended window period, which is conducive to clinical application.
CPC Classifications
A61K 51/0497 A61K 31/4709 A61K 51/0459 A61P 35/00 C07D 215/50 C07D 401/12 C07D 401/14 C07F 5/06 C07F 5/069 C07B 2200/05 C07B 2200/07
Filing Date
2020-10-13
Application No.
18016459
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.